Halozyme Therapeutics, Inc. (HALO) 2011年年度报告「NASDAQ」.pdf

1、Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,D.C.20549 FORM 10-K OR Commission File Number:001-32335 Halozyme Therapeutics,Inc.(Exact name of registrant as specified in its charter)(858)794-8889 (Registrants Telephone Number,Including Area Code)Securities registered

2、under Section 12(b)of the Act:Securities registered under Section 12(g)of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.x Yes No Indicate by check mark if the registrant is not required to file reports pursuant to S

3、ection 13 or 15(d)of the Act.Yes x No Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was required to file such report

4、s),and(2)has been subject to such filing requirements for the past 90 days.x Yes No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site,if any,every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulatio

5、n S-T(232.405 of this chapter)during the preceding 12 months(or for such shorter period that the registrant was required to submit and post such files).x Yes No Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein,and will not be co

6、ntained,to the best of registrants knowledge,in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.x Indicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-accelerated fi